Wertpapiername | Anteil |
---|---|
HALOZYME 1% 2028 | 8,00 % |
GLANBIA COOP 1.875% 2027 | 6,00 % |
SILICON ON INSULATOR 0% 2025 | 5,00 % |
GREEN PLAINS 2.25% 2027 | 5,00 % |
MAKEMYTRIP 0% 2028 | 4,00 % |
IQ 6.5% 2028 | 4,00 % |
ZILLOW 1.375% 2026 | 4,00 % |
JAZZ PHARMACEUTICALS 2% 2026 | 4,00 % |
ZTO EXPRESS 1.5% 2027 | 4,00 % |
BIZLINK 0% 2027 | 4,00 % |
Summe: | 48,00 % |
The sub-fund aims to increase the value of your investment over the long term. Under normal market conditions, the main part of the portfolio is invested in convertible bonds and/or other fixed income securities, bank deposits and warrants or call options on shares and, up to 10% of the sub-fund's assets in units of undertakings for collective investment that represent these asset classes. The sub-fund may also invest in shares or other instruments equivalent to shares and use derivatives for investment purposes or to reduce investment risks (hedging). Based on criteria such as innovation, quality of management, valuation and leadership, the manager selects companies around the world that it believes have strong growth prospects or are undervalued. The product invests in a concentrated portfolio of shares of these companies and/or instruments convertible into shares or giving the right to acquire shares of these companies. The main part of the portfolio is managed in an endeavour to replicate the financial behaviour of a convertible bonds portfolio. To this end, the manager ensures that: (i) at least 50% of the portfolio consists of bonds and other fixed income securities, and (ii) the product's overall exposure to the equity market, through shares and other securities whose price is linked to shares, does not exceed 100% of its net assets. The manager's objective is to hedge positions in currencies other than EUR representing more than 2.5% of the net asset value of the product.